Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 10 | 13 | -0,16 % | ||
| MODERNA | 9 | 16 | -0,67 % | ||
| REVOLUTION MEDICINES | 8 | 5 | +0,44 % | ||
| BIOAGE LABS | 7 | - | -5,50 % | ||
| COMPASS PATHWAYS | 5 | 11 | -0,63 % | ||
| ARROWHEAD PHARMACEUTICALS | 4 | - | -1,25 % | ||
| INCYTE | 3 | 25 | +0,51 % | ||
| REGENERON PHARMACEUTICALS | 3 | 22 | -0,33 % | ||
| DISC MEDICINE | 3 | 7 | -3,30 % | ||
| GILEAD SCIENCES | 3 | 5 | -0,55 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06:12 | Maze Therapeutics, Inc.: Maze Therapeutics Announces $150 Million Registered Offering | 1 | GlobeNewswire (USA) | ||
| 04:42 | 10x Genomics: Atera Platform Launch Advances Spatial Biology With Single-Cell Resolution At Scale | 2 | pulse2.com | ||
| 04:42 | Tyra Biosciences: Board Appointment Of Habib Dable Supports Next Phase Of Growth | 1 | pulse2.com | ||
| 01:30 | Moderna begins phase 3 trial of H5 bird flu vaccine candidate | 3 | Investing.com | ||
| 01:02 | Moderna, Inc.: Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate | 432 | ACCESS Newswire | Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April... ► Artikel lesen | |
| 00:48 | Kyverna Therapeutics, Inc.: Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session ... | 3 | GlobeNewswire (USA) | ||
| Di | Revolution Medicines: Starke Studiendaten zu Bauchspeicheldrüsenkrebs beflügeln Aktie | - | Investing.com Deutsch | ||
| Di | Revolution Medicines presents pancreatic cancer trial data at AACR | 1 | Investing.com | ||
| Di | Eli Lilly terminates license agreement with Rigel over ocadusertib | 3 | Seeking Alpha | ||
| Di | Zymeworks reports phase 1 trial results for ovarian cancer drug | 1 | Investing.com | ||
| Di | Revolution Medicines unveils new RAS cancer inhibitor class | 1 | Investing.com | ||
| Di | Medpace Q1 2026 Earnings Preview | 1 | Seeking Alpha | ||
| Di | Revolution Medicines, Inc.: Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting | 1 | GlobeNewswire (USA) | ||
| Di | Revolution Medicines, Inc.: Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting | 1 | GlobeNewswire (USA) | ||
| Di | Zymeworks Inc.: Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026 | 295 | GlobeNewswire (Europe) | ZW191 demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRa expressionConfirmed objective response rate (cORR) of 61% at doses 6.4-9.6... ► Artikel lesen | |
| Di | Intellia Therapeutics, Inc. (NTLA) Sees Moderate Buy Rating From Analysts | 2 | Insider Monkey | ||
| Di | Annexon Biosciences (ANNX) Buy Rating Retained | 1 | Insider Monkey | ||
| Di | Wechsel im Verwaltungsrat von Xeris Biopharma: Jeffrey Sherman tritt 2026 ab | 1 | Investing.com Deutsch | ||
| Di | GRAIL präsentiert neue Studiendaten zum Krebstest Galleri auf ASCO-Tagung | 1 | Investing.com Deutsch | ||
| Di | Voyager Therapeutics CFO resigns; Robin Swartz takes financial charge | 1 | Seeking Alpha |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.